the new strategies that biotech pharmaceutical companies are implementing in order to survive in today’s medical industry.
The new research, entitled Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends, explores how intellectual property (IP), pipeline and product portfolio enhancement, financial growth, and global market expansion is driving the demand for deals, as the patent cliff, declining R&D productivity, and the increasing costs and risks associated with drug development foster an environment of inorganic growth.
The report highlights deals potentially worth up to $26 billion, which took place between September 2011 and September 2012, with mergers and acquisitions accounting for almost 90% of this value. In particular, therapeutic areas such as oncology and CNS have featured in a significant number of deals, highlighting a huge unmet clinical need – which makes for attractive market potential.
Many licensing deals have also involved cancer therapeutics, such as Baxter’s $565m deal with Onconova Therapeutics in September 19, 2012, for late-stage developmental cancer drug rigosertib. In addition, Janssen Biotech’s $1.1 billion collaboration agreement with Genmab in August 30, 2012, positions Janssen to obtain royalties from daratumumab, Genmab’s experimental cancer drug.
For Sample Pages, please click or add the below link to your browser:
Meanwhile, cancer drugs in development have also been driving acquisitions by biotech companies including Amgen and Celgene, which acquired Micromet and Avila Therapeutics respectively in March 2012. Novartis’ collaboration with the University of Pennsylvania is also primarily driven by an early-stage cancer therapeutic, an example of pharmaceutical companies’ growing interest in early-stage research activities with academic institutions as a result of an industry-wide decline in innovation and an increase in development of “me-too” drugs.
The report also shows an increasing trend for pharmaceutical companies to expand their businesses into emerging markets such as China, Brazil, and India in order to steer away from developed markets including the US and the current European financial crisis.
This report analyzes 20 strategic deals struck by leading and promising biotech companies. The terms and strategic drivers of these deals are analyzed based on acquisition costs, strategic fit, potential revenues, competitive advantage as well as other measures to illustrate the strategies different companies are currently using to gain market share, increase shareholder value and bring innovative and life-saving products to the booming global pharmaceuticals market. The report is an essential source of information and analysis on global strategic deals involving the top players in the global pharmaceuticals market.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
For further details, please click or add the below link to your browser:
Visit our report store: http://www.globaldata.com/
For more details contact:
North America: +1 646 395 5477